Visual Abstract

Introduction: Approximately one third of patients with T2D have cardiovascular disease (CVD). The 2019 ESC and ADA/EASD guidelines recommend glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as either first- or second-line antidiabetic medication in these patients. We aimed to investigate the budget implications of treating patients with CVD with GLP-1 RAs rather than standard of care (SoC).

Methods: GLP-1 RA-naïve adults (≥ 18 years old) with T2D in the IBM MarketScan® database who had a claim for an antidiabetic medication (index date) within 6 months after their first hospitalization for CVD were included. Costs of care per month over the 365 days post-index were compared for those who initiated a GLP-1 RA post-hospitalization versus those with a claim for any other antidiabetic medication (SoC).

Results: Prior to hospitalization, total costs were similar for the two groups. After hospitalization and treatment initiation, adjusted mean total costs were lower, although not significantly, for patients receiving a GLP-1 RA compared with SoC. This was driven by significantly lower inpatient and outpatient costs and significantly higher drug costs (Figure).

Conclusions: These findings suggest that the added cost of treating patients with T2D with GLP-1 RAs is offset by significantly lower inpatient and outpatient care costs after CVD hospitalization, resulting in budget neutrality against SoC.

Disclosure

M. Evans: Consultant; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Novo Nordisk A/S. A. Chandramouli: Employee; Self; Novo Nordisk. M. Faurby: Employee; Self; Novo Nordisk A/S. K. S. Matthiessen: Employee; Self; Novo Nordisk A/S. P. Mogensen: Consultant; Self; Novo Nordisk. S. Verma: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk, Sanofi, Research Support; Self; AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, EOCI Pharmacomm Ltd., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk, Sanofi, Sun Pharmaceutical Industries Ltd., Toronto Knowledge Translation Working Group.

Funding

Novo Nordisk A/S

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.